



Summit Sentinel

Working for a Victory Over Parkinson's

www.SummitforStemCell.org

UPDATE: Cell Replacement Therapies for PD Around the World

Kyoto, Japan. (Kyoto University) The first clinical trial using allogeneic iPSC cells to generate dopamine neurons to transplant to people with PD was started in 2018, and the 7-person trial was completed in 2021. There were no safety issues reported. Results are expected to be reported in 2024. The work was developed in the lab of Dr. Jun Takahashi.

United States, New York (Blue Rock Therapeutics, division of Bayer Global). An embryonic stem cell line (called WA09) was used to generate dopaminergic neurons, which were transplanted in a Phase 1 trial to the first of 12 patients in 2021. The remaining trial is expected to be complete by mid-2023, with the results announced in 2024. The plans originated in the laboratory of Dr. Lorenz Studer at Memorial Sloan Kettering Cancer Center in New York City. Bayer is also investigating a gene therapy to introduce the growth factor, GDNF, into cells of the brain.

Sweden (STEM-PD) Transplantation of dopamine neurons derived from an embryonic stem cell line was approved in October to begin candidate selection for a clinical trial. This is a collaborative effort led by Dr. Malin Parmar (Lund University), Dr. Roger Barker (Wellcome-MRC Stem Cell Inst., Univ. of Cambridge); others include Drs. Agnete Kirkeby, Gesine Paul-Visset, Hakan Widner, Hjalmar Bjartmarz, and Paola Piccini. The STEM-PD trial will assess safety and tolerability one year after transplantation, measuring the effects on PD symptoms. The first trial of 8 patients first from Sweden, plans for enrolment from both Sweden and from Cambridge University. All transplantation surgery will be performed at Skåne Univ. Hosp. in Lund. Patient selection is by invitation only. It is not possible to volunteer for these trials.

United States, San Diego, CA (Aspen Neuroscience). Aspen Neuroscience has not yet begun a clinical trial but is expected to apply to the FDA soon. The cell-replacement therapy was developed by the lab of Jeanne F. Loring at the Scripps Research Institute and uses autologous iPSC-derived dopamine neurons derived from each person in the study, with the goal of avoiding the immunosuppression required for the allogeneic iPSC and human embryonic stem cell trials.

Our Mission

Summit for Stem Cell Foundation's mission is to support, educate and raise awareness about the development of today's and tomorrow's evidence-based regenerative medical therapies focused on **Parkinson's disease** and other neurodegenerative disorders. It is our goal to empower patients and caregivers with information to elevate their understanding in order to manage their healthcare.

Our Programs

- Research Program
- Education Program
- Patient Support Program

For more info:
www.SummitforStemCell.org

WE need your help.

Summit is a 510(c)(3) charitable organization dependent on your support. All donations are tax-exempt. Tax ID #47-4279391

"MOTIVATION comes from working on things we care about" - Sheryl Sandberg

DONATE TODAY



UPCOMING EVENTS

CME WEBINAR SCHEDULE

Tues., Jan. 10, 2023

5:00-7:00pm

The History of Stem Cells

Featuring : Jeanne Loring, PhD

.....

Tues., Feb. 07, 2023

5:00-7:00pm

CIRM

Featuring:

Rosa Canet-Aviles., PhD

.....

Date: TBD

Featuring:

Randy Schekman, PhD

.....

**MDs, RNs, and the public
WELCOME!**

.....

Registration: FREE

All webinars are subject to change

All at 5:00-7:00pm

Our WEBSITE is updated regularly to keep you informed on the latest news.

We appreciate your interest and patience. Help us help you stay informed.

Please DONATE TODAY



SUMMIT WELCOMES NEW SPONSORS!

Summit is proud to welcome two new sponsors for our educational programs – specifically, our Continuing Medical Education (CME & Non-CME) webinar series.



The California Institute for Regenerative

Medicine (CIRM) was created by the people of California to accelerate stem cell treatments to

patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. CIRM awarded Summit a \$50,000 grant in educational support efforts.



Aspen Neuroscience, Inc. provided \$10,000 in

support of Summit's Continuing Medical Education (CME & Non-CME) webinar series.

Our CME & Non-CME webinar series strives to keep our attendees informed about fast-paced scientific discoveries. Featured guest speakers are leaders in their respective fields. *i.e.*, Alberto Espay, MD, MSc, FAAN, FANA; Roger Barker, BA, MBBS, MRCP, PhD; Peter Marks, MD, PhD; and many more.

Past webinars are available to view on our website.

Upcoming CME & Non-CME Webinars feature: Jeanne Loring, PhD; Aspen Neuroscience; Peter Marks, MD, PhD; and Nobel laureate Randy Schekman, PhD and many more.

CME & Non-CME Webinars are attended by scientists, researchers, students, academia, industry professionals, medical community members, and patients. Our attendees are located across the United States and from around the world.

Jeanne Loring generally moderates each webinar.

If you haven't attended one of our educational webinars – please do! Watch for updates on upcoming webinars.

More info about our CME & Non-CME webinars

Thanks to you, our supporters, we are making progress towards a Victory Over Parkinson's. Please remember Summit for your year-end charitable contributions.

"Individually, we are one drop.

TOGETHER, we are an ocean"

-R. Satoro